First-in-Kind Immunotherapy for Atrial Fibrillation
Atrial fibrillation is the most common cardiac arrhythmia, affecting tens of millions of people worldwide. It is currently a chronic condition with no cure and increased morbidity over time. All current treatments manage symptoms, not the physiological root causes of atrial fibrillation. Based on our preclinical evidence to-date, there is good reason to think human cardiac exosome therapy may be a breakthrough.
Founded by cardiologist, electrophysiologist and scientist Dr. Darryl Davis at the University of Ottawa Heart Institute. The company is a preclinical-stage startup focused on addressing a critical unmet need: preventing and treating atrial fibrillation, a chronic, progressive, debilitating, and life-threatening disease.
Our initial focus is on a preventative solution to postoperative atrial fibrillation. RBex is a prophylactic exosome therapy that has demonstrated an 87% reduction in postoperative atrial fibrillation in extensive and published preclinical studies. We are currently raising funds for a first-in-human phase 1 clinical trial.
Latest News, Presentations & Papers
NEWS
Darryl Davis is honoured to co-chair the 2025 conference of the American Association of Extracellular Vesicles in Salt Lake City, UT
November 20, 2025, AAEV2025
NEWS
“Finding its rhythm: Startup seeks $4M in funding for trailblazing atrial fibrillation treatment”
November 15, 2024, Ottawa Business Journal
PRESENTATION
“Exosome-Based Prevention of Postoperative Atrial Fibrillation”
June 15th, 2024, in Taiyuan China, at the International Forum on Cardiovascular Disease, Stem Cells and Tissue Engineering
PAPER
“Exploring Patient Viewpoints to Optimize Implementation of a Biological Therapy for Atrial Fibrillation Prevention”
April 16, 2024, CJC Open
PAPER
“Extracellular vesicle microRNA and protein cargo profiling in three clinical-grade stem cell products reveals key functional pathways”
June 13, 2023, Molecular Therapy Nucleic Acids
Presentation
"Biodistribution, Safety and Efficacy of Extracellular Vesicle-based Prevention of Atrial Fibrillation in Murine and Porcine Models of Sterile Pericarditis"
April 22, 2025, Heart Rhythm Society HRS25
PRESENTATION
“Human extracellular vesicles prevent inflammation and fibrosis in a human model of postoperative atrial fibrillation”
November 10, 2024, Houston, Texas, at the American Association of Extracellular Vesicles AAEV2024 conference
PAPER
“RNA and the emerging potential of bio-inspired molecules in cardiovascular disease therapies”
June 13, 2024, European Heart Journal
PAPER
“Inactivation of the NLRP3 inflammasome mediates exosome-based prevention of atrial fibrillation”
January 1, 2024, Theranostics
NEWS
"Capital BioVentures Announces Inaugural Cohort for Ottawa Biotech Accelerator Program"
December 3, 2024, BioSpace
PRESENTATION
“Extracellular Vesicle Therapy for Atrial Fibrillation” and “Arrhythmias in a Model of Chronic Inflammation”
September 26, 2024, Sydney Australia, at the Asia Pacific Heart Rhythm Society 2024 conference
PAPER
“Atrial Fibrosis and Inflammation in Postoperative Atrial Fibrillation: Comparative Effects of Amiodarone, Colchicine, or Exosomes”
June 10, 2024, JACC Clinical Electrophysiology
PAPER
“Prevention of atrial fibrillation after open-chest surgery with extracellular vesicle therapy”
June 29, 2023, JCI Insight
Contact Us
H3214 40 Ruskin St.
Ottawa, Ontario K1Y 4W7 Canada
+1-613-696-7298
